Anti TIGIT Therapies Market Insight 2023
26 juin 2023 07h12 HE
|
KuicK Research
Delhi, June 26, 2023 (GLOBE NEWSWIRE) -- Global Anti TIGIT Antibody Clinical Trials and Companies Insight 2023 Report Highlights: Global Anti TIGIT Antibodies Market DynamicsInsight On Anti...
Coherus and Junshi Biosciences Expand Immuno-Oncology Collaboration to Include TIGIT-Targeted Antibody
10 janv. 2022 07h30 HE
|
Coherus BioSciences, Inc.
• Coherus and Junshi Biosciences plan to evaluate the toripalimab + JS006 combinationin clinical trials in multiple tumor types • Combinations of PD-1 + TIGIT inhibitors have potential to expand...
Cascadian Therapeutics Highlights Preclinical Program Presentations at the American Association for Cancer Research Annual Meeting 2017
05 avr. 2017 08h00 HE
|
Cascadian Therapeutics, Inc.
SEATTLE, April 05, 2017 (GLOBE NEWSWIRE) -- Cascadian Therapeutics, Inc. (NASDAQ:CASC), a clinical-stage biopharmaceutical company, today announced data highlights from presentations of preclinical...
OncoMed Pharmaceuticals Announces Fourth Quarter and Full Year 2016 Financial Results
08 mars 2017 16h05 HE
|
OncoMed Pharmaceuticals, Inc.
Demcizumab and Tarextumab Randomized Phase 2 Data Expected 1H 2017 Anti-TIGIT IND Accepted; GITRL-Fc IND Expected 1H 2017 OncoMed Management to Host Conference Call/Webcast this Afternoon at 4:30...
OncoMed Announces Multiple Abstracts Related to Anti-TIGIT Program Accepted for Presentation at the American Association for Cancer Research Annual Meeting 2017
02 mars 2017 08h30 HE
|
OncoMed Pharmaceuticals, Inc.
REDWOOD CITY, Calif., March 02, 2017 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals Inc. (NASDAQ:OMED) will present new data related to its clinical and preclinical immuno-oncology and anti-cancer stem...
OncoMed Announces Year-End Cash Balance and 2017 Outlook
05 janv. 2017 08h30 HE
|
OncoMed Pharmaceuticals, Inc.
Enters 2017 with $184.6 Million in Cash Potential for Five Program Opt-ins Totaling Over $170M Anti-TIGIT (I/O#2) IND Filed REDWOOD CITY, Calif., Jan. 05, 2017 (GLOBE NEWSWIRE) -- OncoMed...